Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
作者： Donna L. Forrest , Shannon Trainor , Ryan R. Brinkman , Michael J. Barnett , Donna E. Hogge
DOI: 10.1016/J.LEUKRES.2008.07.015
关键词: Imatinib 、 Major Molecular Response 、 Medicine 、 Complete Cytogenetic Response 、 Plasma levels 、 Gastroenterology 、 Myeloid leukemia 、 Sokal Score 、 Immunology 、 Internal medicine 、 Framingham Risk Score 、 Trough (economics)
摘要: Cytogenetic and molecular responses to standard-dose imatinib (IM) were correlated with trough IM plasma levels for 78 patients chronic myeloid leukemia (CML) after a minimum of 12 months therapy. The mean level was 1065 ng/ml (range, 203-2910). There no correlation complete cytogenetic response (CCR) at 1 year (CCR 1010 vs CCR 1175 P=.29) or major (MMR) (MMR1067 MMR 1063 P=.74) median 1298 days did correlate Sokal risk scores the odds achieving low high score 10.8 (95% CI 2.2-53.5) 6.4 1.4-29.4), respectively. Furthermore, longer duration therapy also associated greater likelihood (P=.02).
elsevier.com
sci-hub.se 参考文章(11)
Julia Thomas, Lihui Wang, Richard E. Clark, Munir Pirmohamed, Active Transport of Imatinib into and Out of Cells: Implications for Drug Resistance Blood. ,vol. 104, pp. 3739- 3745 ,(2004) , 10.1182/BLOOD-2003-12-4276
Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud, Nicholas Moore, Mathieu Molimard, Francois-Xavier Mahon, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood. ,vol. 109, pp. 3496- 3499 ,(2007) , 10.1182/BLOOD-2006-07-036012
Tim Hughes, Susan Branford, Molecular monitoring of chronic myeloid leukemia. Seminars in Hematology. ,vol. 40, pp. 62- 68 ,(2003) , 10.1053/SHEM.2003.50044
T Illmer, M Schaich, U Platzbecker, J Freiberg-Richter, U Oelschlägel, M von Bonin, S Pursche, T Bergemann, G Ehninger, E Schleyer, P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. ,vol. 18, pp. 401- 408 ,(2004) , 10.1038/SJ.LEU.2403257
Richard A. Larson, Brian J. Druker, Francois Guilhot, Stephen G. O'Brien, Gilles J. Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood. ,vol. 111, pp. 4022- 4028 ,(2008) , 10.1182/BLOOD-2007-10-116475
Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, Timothy Hughes, Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood. ,vol. 110, pp. 4064- 4072 ,(2007) , 10.1182/BLOOD-2007-06-093617
A Hochhaus, P La Rosée, Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance Leukemia. ,vol. 18, pp. 1321- 1331 ,(2004) , 10.1038/SJ.LEU.2403426
Tim P. Hughes, Jaspal Kaeda, Susan Branford, Zbigniew Rudzki, Andreas Hochhaus, Martee L. Hensley, Insa Gathmann, Ann E. Bolton, Iris C. van Hoomissen, John M. Goldman, Jerald P. Radich, Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia New England Journal of Medicine. ,vol. 349, pp. 1423- 1432 ,(2003) , 10.1056/NEJMOA030513
Brian J. Druker, François Guilhot, Stephen G. O'Brien, Insa Gathmann, Hagop Kantarjian, Norbert Gattermann, Michael W.N. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice L. Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John Shepherd, Giuseppe Saglio, Alois Gratwohl, Johan L. Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia The New England Journal of Medicine. ,vol. 355, pp. 2408- 2417 ,(2006) , 10.1056/NEJMOA062867
Gianantonio Rosti, Giovanni Martinelli, Simona Bassi, Marilina Amabile, Elena Trabacchi, Barbara Giannini, Daniela Cilloni, Barbara Izzo, Antonio De Vivo, Nicoletta Testoni, Giovanna Rege Cambrin, Francesca Bonifazi, Simona Soverini, Simona Luatti, Enrico Gottardi, Daniele Alberti, Fabrizio Pane, Francesco Salvatore, Giuseppe Saglio, Michele Baccarani, , Molecular response to imatinib in late chronic-phase chronic myeloid leukemia Blood. ,vol. 103, pp. 2284- 2290 ,(2004) , 10.1182/BLOOD-2003-07-2575